Recent News
Welcome to Immuven
April 1, 2012
ImmuVen Receives $1.67 Million Phase II SBIR Award From NIH
- ImmuVen was awarded a Phase II SBIR totaling $1.67 million from the National Institute for Allergy and Infectious Disease for continuing development of therapeutics to neutralize Staphylococcal aureus toxins. For more information, click here.
ImmuVen develops novel drugs that can be used to treat infectious diseases and cancer. The company is located in Champaign, Illinois at the University of Illinois Research Park.
The company features a powerful, emerging life science technology, T cell receptors, a unique class of immune-targeting therapeutic and diagnostic agents. These agents have significant advantages over antibodies, which are already a $20 billion/year market against cancer, autoimmune, and infectious diseases.
